RxDoctor Payments Data

Charles Kaplan, MD

Urology · Austell, GANPI 1538261227

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,537 of the $16,607 with a category attached, or 75.5%. 42 manufacturers reported payments, led by Boston Scientific at 38.4% of the total.

$16,607in general payments, 2019–2025

Across 402 payments — averaging $41.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Coloplast$3K
  • Medtronic$1K
  • Teleflex LLC$702
  • Johnson & Johnson$530
  • Astellas Pharma US Inc$504
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$800%
  • Speaking & faculty fees$2,50015%
  • Travel & lodging$1,1267%
  • Food & beverage$12,53775%
  • Education$3642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,607 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$279,591
Medicare patients
687
Services billed
6,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide23$333,738
XtandiEnzalutamide16$223,534
GemtesaVibegron116$75,043
OrgovyxRelugolix22$58,279
MyrbetriqMirabegron81$57,247
Testosterone90$13,064
Tamsulosin Hcl671$6,873
Potassium Citrate ErPotassium Citrate42$3,861
Alfuzosin Hcl ErAlfuzosin Hcl204$3,542
Fesoterodine Fumarate ErFesoterodine Fumarate28$3,490
Finasteride282$3,225
Solifenacin Succinate90$3,008
Methenamine Hippurate72$2,989
Testosterone Cypionate70$2,827
Estradiol26$2,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$530$333,73823 claims
Astellas Pharma US IncXtandi, Myrbetriq$504$280,78097 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$339$133,322138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.

Other urology in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →